Pre-Test Effective Risk Stratification And Expert Treatment Selection Advice For Patients With Myelodysplastic Syndromes Pre-Test Which of the following models provides the most accurate risk prediction for patients with myelodysplastic syndromes? WPSS MDAC MDS Model IPSS-M IPSS-R Unsure Which of the following therapeutics is recommended for treating patients with SF3B1 mutations classified as low-risk for progression to AML? Ivosidenib Lenalidomide Luspatercept Venetoclax Unsure To what maximal dose should luspatercept be escalated in case of lack of response before abandoning therapy (in the absence of unacceptable toxicity? 0.8 mg/kg 1 mg /kg 1.33 mg/kg 1.75 mg/kg Unsure How confident are you in your ability to use risk stratification tools to categorize patients with MDS? Very confident Confident Somewhat confident Not very confident Not at all confident
